The convergence of artificial intelligence (AI) and nanotechnology offers transformative potential in the diagnosis, monitoring, and treatment of breast cancer. This chapter explores how AI-driven strategies are revolutionizing nanomedicine, enabling smarter, faster, and more precise approaches in oncology. Beginning with a foundational introduction to AI concepts, the chapter outlines how intelligent nanosystems are being leveraged for real-time monitoring, early detection, high-sensitivity imaging, and tumor characterization, promising a new era of precision cancer diagnostics. The integration of AI into the rational design of nanocarriers is examined in detail, including ligand optimization, controlled drug release, and multifunctional nanoparticle development. Special attention is given to the role of data mining, and machine learning in enhancing nanodrug discovery and design. Moreover, the chapter highlights how AI facilitates real-time optimization of the nano-biointerface by decoding cellular uptake mechanisms, intracellular trafficking, and downstream biological responses through molecular simulations and predictive analytics. Key focus is placed on personalized nanomedicine, where AI enables the development of predictive models for therapeutic response and pharmacogenetic-guided dosing tailored to individual patient profiles. The chapter concludes with a critical discussion of the challenges and future outlook of AI-integrated nanotechnologies in oncology, emphasizing ethical considerations, data quality, and clinical translation. By bridging computational intelligence with nanoscale engineering, this chapter shows a cutting-edge framework for advancing breast cancer care toward smarter, more effective, and patient-specific therapeutic paradigms.